Contracts › 75N95020F00001
75N95020F00001: Non-Clinical Safety Assessment of Gene Therapy (Pcca, Mmab, DOK7 and Colq) to Support Platform Gene Therapy for Congenital Myasthenic Diseases (DOK7, COLQ) and Acidemia (PCCA, MMAB)
Awarded to Lovelace Biomedical Research Institute by National Institutes of Health (NIH).
$5.3Mobligated
$8.1Mpotential value
31 May 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N95020F00001 |
|---|---|
| Vehicle | HHSN271201700017I |
| Awardee | Lovelace Biomedical Research Institute |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NATIONAL INSTITUTES OF HEALTH NIDA |
| NAICS | 541712 Research and Development in the Physical, Engineering, and Life Sciences (Except Biotechnology) |
| PSC | AN11 Health R&D Services; Health Care Services; Basic Research |
| Place of performance | NM |
| Offers received | 3 |
| Period of performance | 25 September 2020 to 31 May 2027 |
| Potential end | 31 May 2027 |
| Estimated recompete solicitation | ~Q4 2026 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541712 contracts · All expiring contracts · USASpending record